• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • ADDICTION & DOPAMINE
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING BRAIN
      • FASTING CANCER
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME EXTRACT
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    PHLORIZIN
    September 21, 2021
    GLUCONEOGENESIS
    September 21, 2021
    1. Inhibition of Renal Glucose Reabsorption: a novel strategy for achieving Glucose control in type 2 diabetes mellitus
    2. Inhibition of Renal Glucose Reabsorption as a novel treatment for diabetes patients
    3. Renal Glucose Reabsorption inhibitors to treat diabetes
    4. Characterization of Renal Glucose Reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
    5. Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in Renal Glucose Reabsorption in humans
    6. Development of the Renal Glucose Reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2
    7. Effect of Lepidium sativum L. on Renal Glucose Reabsorption and urinary TGF‐β1 levels in diabetic rats
    8. Selective SGLT2 Inhibition by tofogliflozin reduces Renal Glucose Reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats
    9. Antihyperglycemic effect of T-1095 via Inhibition of Renal Na+-Glucose cotransporters in streptozotocin-induced diabetic rats
    10. Renal Glucose transporters: novel targets for hyperglycemia management
    11. Role of the kidney in normal Glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
    12. Renal, metabolic and cardiovascular considerations of SGLT2 Inhibition
    13. Sodium-Glucose cotransporter-2 Inhibition and the glomerulus: a review
    14. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
    15. Type 2 sodium-Glucose cotransporter (SGLT2) inhibitors: from familial Renal glucosuria to the treatment of type 2 diabetes mellitus
    16. Inhibition of the intestinal sodium‐coupled Glucose transporter 1 (SGLT1) by extracts and polyphenols from apple reduces postprandial blood Glucose levels in mice …
    17. Glucose metabolism in the kidney: neurohormonal activation and heart failure development
    18. The role of the kidney and sodium-Glucose cotransporter-2 Inhibition in diabetes management
    19. Effect of phlorhizin on Renal Glucose and phosphate transport in the dog
    20. Exploring newer target sodium Glucose transporter 2 for the treatment of diabetes mellitus
    21. Glucose control by the kidney: an emerging target in diabetes
    22. Targeting Renal Glucose Reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin
    23. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus
    24. Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors
    25. Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes
    26. Dapagliflozin: a sodium Glucose cotransporter 2 inhibitor in development for type 2 diabetes
    27. SGLT2 Inhibition in diabetes mellitus: rationale and clinical prospects
    28. Effect of sodium-Glucose cotransport Inhibition on polycystic kidney disease progression in PCK rats
    29. Sodium Glucose co-transporter 2 (SGLT2) inhibitor
    30. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary Glucose excretion in healthy subjects
    31. The role of the kidneys in Glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium Glucose co-transporter 2 …
    32. SGLT2 Inhibition—a novel strategy for diabetes treatment
    33. Tofogliflozin, a potent and highly specific sodium/Glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice
    34. SGLT2 inhibitors: molecular design and potential differences in effect
    35. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin–nicotinamide-induced mildly diabetic mice
    36. Sodium‐Glucose co‐transporter (SGLT) and Glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects
    37. Does urea Reabsorption occur via the Glucose pathway in the kidney of the freshwater rainbow trout?
    38. Model analysis of effect of canagliflozin (Invokana), a sodium–Glucose cotransporter 2 inhibitor, to alter plasma 1, 5-anhydroglucitol
    39. Modified cycloartanes with improved inhibitory effect on SGLT-mediated Glucose uptake in human Renal proximal tubular cells
    40. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
    41. Phlorizin-like effect of Fraxinus excelsior in normal and diabetic rats
    42. Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjects
    43. Hypoglycaemic activity of Retama raetam in rats
    44. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-Glucose co-transporter type 2
    45. Role of the kidney in Glucose homeostasis: implications for SGLT-2 Inhibition in the treatment of type 2 diabetes mellitus
    46. Sodium-Glucose co-transport inhibitors
    47. Dapagliflozin: a selective sodium-Glucose co-transporter-2 inhibitor in type 2 diabetes.
    48. In vitro–in vivo correlation of the Inhibition potency of sodium-Glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach
    49. Siphoning Blood Glucose: A Novel Therapy
    50. T-1095, a Renal Na+-Glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats
    51. The role of the kidneys in Glucose homeostasis: a new path towards normalizing glycaemia
    52. Dapagliflozin, a selective SGLT2 inhibitor, improves Glucose homeostasis in normal and diabetic rats
    53. Sodium Glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes
    54. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent Glucose co-transporter 2, in …
    55. Targeting the kidney and Glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 Inhibition as a new option for treatment of type 2 …
    56. Lowering plasma Glucose concentration by inhibiting Renal sodium–Glucose cotransport
    57. Development of the sodium-Glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus
    58. Physiologically based pharmacokinetic–pharmacodynamic modeling to predict concentrations and actions of sodium‐dependent Glucose transporter 2 inhibitor …
    59. Novel SGLT 2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected Renal effects
    60. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta‐analysis
    61. Associations of insulin levels and insulin resistance with urine Glucose excretion independent of blood Glucose in Chinese adults with prediabetes and newly …
    62. Unmasking and aggravation of polycythemia vera by canagliflozin
    63. Effects of Kaempferia parviflora Extract on Glucose Transporters in Human Renal Proximal Tubular Cells
    64. Renal sodium-Glucose cotransporter Inhibition in the management of type 2 diabetes mellitus
    65. Meet the SGLT2 inhibitors: these new type 2 diabetes medications block Glucose Reabsorption by the kidneys
    66. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
    67. Sodium-Glucose co-transporters and their Inhibition: clinical physiology
    68. The combinatorial effective approach of alpha-glucosidase inhibitor and Sodium-Glucose co-transporter 2 (SGLT-2)
    69. Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes
    70. SODIUM-Glucose TRANSPORTER 2 Inhibition–A POTENTIAL OPTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
    71. SGLT2 inhibitors for type 2 diabetes
    72. Risk of erythrocytosis during concomitant testosterone and SGLT2-inhibitor treatment: a warning from two clinical cases
    73. SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?
    74. Antidiabetic drugs and the kidney
    75. Differentiating sodium-Glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
    76. Renal olfactory receptor 1393 contributes to the progression of type 2 diabetes in a diet-induced obesity model
    77. Tofogliflozin: the road goes ever on
    78. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
    79. Distribution of Glucose transporters in Renal diseases
    80. New potent antihyperglycemic agents in db/db mice: Synthesis and structure− activity relationship studies of (4-substituted benzyl)(trifluoromethyl) pyrazoles and …
    81. The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
    82. Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C‐MDG
    83. Dapagliflozin attenuates Renal gluconeogenic enzyme expression in obese rats
    84. Sodium–Glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes
    85. A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy …
    86. Sodium Glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus
    87. A paradigm shift in diabetes therapy—dapagliflozin and other SGLT2 inhibitors
    88. Canagliflozin, a sodium Glucose co-transporter 2 inhibitor, for the management of type 2 diabetes
    89. Empagliflozin, a sodium Glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
    90. Mechanistic evaluation of the effect of sodium‐dependent Glucose transporter 2 inhibitors on delayed Glucose absorption in patients with type 2 diabetes mellitus …
    91. The Role of the Kidney in Glucose Homeostasis
    92. Natural products as lead compounds for sodium Glucose cotransporter (SGLT) inhibitors
    93. Role of sodium-Glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
    94. The Kidneys in Type 2 Diabetes Disturbed Glucose Homeostasis to Mechanism-Based Therapy
    95. Sodium-Glucose cotransporter 2 Inhibition in type 1 diabetes: simultaneous Glucose lowering and Renal protection?
    96. Kidney in diabetes: from organ damage target to therapeutic target
    97. The Renal effects of SGLT2 inhibitors and a mini-review of the literature
    98. Preventive effects of flavonoids on alloxan-induced diabetes mellitus in rats
    99. Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors
    100. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–Glucose co‐transporter type 2, in Japanese subjects without and with …
    101. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐Glucose co‐transporter‐2, in people with type 2 diabetes mellitus
    102. Potent sodium/Glucose cotransporter SGLT1/2 dual Inhibition improves glycemic control without marked gastrointestinal adaptation or colonic microbiota changes in …
    103. DAPA-HF trial: dapagliflozin evolves from a Glucose-lowering agent to a therapy for heart failure
    104. Dapagliflozin: A new drug for treatment of type 2 diabetes mellitus
    105. Dapagliflozin for the treatment of type 2 diabetes
    106. Improved diabetic syndrome in C57BL/KsJ‐db/db mice by oral administration of the Na+‐Glucose cotransporter inhibitor T‐1095
    107. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
    108. Sodium-Glucose co-transporter-2 drugs: are we sure they are useful only in the treatment of diabetes?
    109. p63 and SOX2 dictate Glucose reliance and metabolic vulnerabilities in squamous cell carcinomas
    110. Role of sodium/Glucose cotransporter Inhibition on a rat model of angiotensin II–dependent kidney damage
    111. Dapagliflozin: a review on efficacy, clinical effectiveness and safety
    112. Increased waist-to-hip ratio is associated with decreased urine Glucose excretion in adults with no history of diabetes
    113. EMPA-REG OUTCOME: the nephrologist’s point of view
    114. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
    115. Effect of Renal impairment on the pharmacokinetics and pharmacodynamics of tofogliflozin (a selective SGLT2 inhibitor) in patients with type 2 diabetes …
    116. Structure-activity relationships of preventive effects of flavonoids in alloxan-induced diabetes mellitus in rats
    117. Acute diuretic effect of aqueous extract of Retama raetam in normal rats
    118. Sodium Glucose Co transporter 2 (SGLT2) Inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
    119. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent Glucose cotransporter 2 and clinical candidate for the …
    120. Impact of sodium–Glucose cotransporter 2 inhibitors on blood pressure
    121. Renal gluconeogenesis in insulin resistance: A culprit for hyperglycemia in diabetes
    122. Effect of sodium‐Glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
    123. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
    124. SGLT2 inhibitors in patients with type 2 diabetes and Renal disease: overview of current evidence
    125. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
    126. Sodium-Glucose Transporter 2 Inhibitors and Kidney
    127. Use of Sodium–Glucose Cotransporter 2 (SGLT-2) Inhibitors Beyond Diabetes: On the Verge of a Paradigm Shift?
    128. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes
    129. Pharmacogenetics of novel Glucose-lowering drugs
    130. Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate Renal impairment
    131. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
    132. Short commentary on empagliflozin and its potential clinical impact
    133. Caraway and caper: potential anti-hyperglycaemic plants in diabetic rats
    134. The novel role of the kidney in diabetes management: Sodium-Glucose Co-Transporter 2 Inhibitors
    135. Study of the hypoglycaemic activity of Lepidium sativum L. aqueous extract in normal and diabetic rats
    136. Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-Glucose transporters (SGLTs) in mice
    137. Long-term study of patients with type 2 diabetes and moderate Renal impairment shows that dapagliflozin reduces weight and blood pressure but does not …
    138. Evolution of sodium Glucose co-transporter 2 inhibitors as anti-diabetic agents
    139. Use of a sodium–Glucose cotransporter 2 inhibitor in a patient with chronic kidney disease
    140. Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’
    141. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
    142. Identification of phlorizin binding domains in sodium-Glucose cotransporter family: SGLT1 as a unique model system
    143. Role of genetic variation in the human sodium–Glucose cotransporter 2 gene (SGLT2) in Glucose homeostasis
    144. Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
    145. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
    146. Biopharmacological studies of the aqueous extract of Lepidium sativum seeds in alloxan-induced diabetes in rats
    147. The sodium Glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores Glucose homeostasis in the male zucker diabetic fatty rat
    148. Renal and cardiac implications of sodium Glucose cotransporter 2 (SGLT2) inhibitors: the state of the science
    149. Improved Glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of …
    150. SGLT2i: A novel approach to managing type 2 diabetes
    151. Renal effects of sodium–Glucose cotransporter-2 inhibitors in patients with type 2 diabetes and Renal impairment
    152. Sodium–Glucose Cotransporter 2 Inhibitor–Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review
    153. Patient considerations in the management of type 2 diabetes–critical appraisal of dapagliflozin
    154. Clinical relevance of the selectivity of sodium-Glucose cotransporter-2 inhibitors.
    155. Ipragliflozin, a sodium–Glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes
    156. A Review on Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus
    157. Protection of the kidney with sodium–Glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials
    158. Canagliflozin, a sodium Glucose co-transporter 2 inhibitor, reduces post-meal Glucose excursion in patients with type 2 diabetes by a non-Renal mechanism …
    159. SGLT Inhibition: a possible adjunctive treatment for type 1 diabetes
    160. Sodium-Glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus
    161. Update review of the safety of sodium-Glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus
    162. Sodium-coupled Glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application
    163. Preclinical Species and Human Disposition of (1S, 2S, 3S, 4R, 5S)-5-[4-Chloro-3-(4-ethoxybenzyl) phenyl]-1-hydroxymethyl-6, 8-dioxabicyclo [3.2. 1] octane-2 …
    164. Regulation of Renal brush-border Glucose transport in response to metabolic dysregulation
    165. Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-Glucose cotransporter 2) Inhibition
    166. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study
    167. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects
    168. Sodium-Glucose cotransporter 2 inhibitors: the pleiotropic mechanisms of actions
    169. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient presenting with acute pancreatitis
    170. An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
    171. Type 2 diabetes: An updated overview
    172. SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose
    173. Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
    174. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
    175. Sugar absorption
    176. Role of the kidney and SGLT-2 Inhibition in type 2 diabetes mellitus
    177. SGLT2 inhibitors: not just another Glucose-lowering agent
    178. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
    179. The use of sodium-Glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations
    180. Hypoglycemic activity of methanolic extract of Tectona grandis linn. Root in alloxan induced diabetic rats
    181. Effect of the desert plant Retama raetam on glycaemia in normal and streptozotocin-induced diabetic rats
    182. Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium Glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus
    183. Metformin supports the antidiabetic effect of a sodium Glucose cotransporter 2 inhibitor by suppressing endogenous Glucose production in diabetic mice
    184. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review
    185. High urinary Glucose is associated with improved Renal prognosis in patients with diabetes mellitus
    186. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
    187. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized …
    188. SGLT2 inhibitors–a potential treatment for Alport syndrome
    189. Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage …
    190. Development of sodium-dependent Glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics
    191. Lepidium species as antidiabetic herbal medicines
    192. Pathophysiology of Type 2 Diabetes
    193. The effect of saffron (Crocus sativus L.) and its ingredients on the management of diabetes mellitus and dislipidemia
    194. Luseogliflozin: first global approval
    195. A mechanistic investigation into the acute effects of apple polyphenols on carbohydrate digestion and absorption
    196. The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
    197. The potential role of sodium Glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
    198. Glucose lowering efficacy and pleiotropic effects of sodium-Glucose cotransporter 2 inhibitors
    199. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
    200. Diabetes Mellitus, Obesity and Phytotherapy
    201. Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
    202. Ethnobotanical Survey of Medicinal Plants Used by Traditional Healers to Treat Diabetes in the Taza Region of Morocco
    203. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
    204. Initial experience of SGLT2 inhibitor use in type 2 diabetes
    205. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes
    206. Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the Renal …
    207. Pharmacologic management of type 2 diabetes mellitus: available therapies
    208. Hypoglycaemic effect of Triticum repens P. Beauv. in normal and diabetic rats
    209. Effects of diuretics on sodium-dependent Glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
    210. Mechanism and efficacy of new anti-diabetic medications
    211. Cardiovascular effects of sodium Glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus
    212. Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes …
    213. Inhibitors of sodium-Glucose linked transporter 2-A new class antidiabetic drugs used for the treatment of diabetes mellitus type 2
    214. Antinociceptive activity of aqueous extract of Lepidium sativum L. in mice
    215. Combination therapy for type 2 diabetes: dapagliflozin plus metformin
    216. A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant …
    217. Use of canagliflozin in combination with and compared to incretin-based therapies in type 2 diabetes
    218. Comparisons of weight changes between sodium‐Glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes …
    219. Diabetes and medicinal plants-A review
    220. Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats
    221. Role of insulin in the abnormal glucagon secretory response to hypoglycemia in type 1 diabetes
    222. The new direction in medical
    223. Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes
    224. Novel avenues for treating diabetic nephropathy: new investigational drugs
    225. Effects of phlorizin on vascular complications in diabetes db/db mice
    226. A review: antidiabetic medicinal plants used for diabetes mellitus
    227. Apple polyphenol-rich drinks dose-dependently decrease early-phase postprandial Glucose concentrations following a high-carbohydrate meal: a randomized …
    228. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study
    229. ANTI-HYPERGLYCAEMIC EFFECT OF SOME UNANI FORMULATIONS IN THE MANAGEMENT OF DIABETES MELLITUS TYPE 2
    230. Drug off-target effects predicted using structural analysis in the context of a metabolic network model
    231. Effects of Zanthoxylum zanthoxyloides leaves on blood Glucose, lipid profile and some liver enzymes in alloxan induced diabetic rats
    232. Early administration of empagliflozin preserved heart function in cardioRenal syndrome in rat
    233. The sodium Glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes
    234. Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
    235. Efficacy and safety of sodium‐Glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
    236. Energy loss via urine and faeces–a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight
    237. Sodium Glucose co-transporter-2 inhibitor: benefits beyond glycemic control
    238. Ketone bodies for kidney injury and disease
    239. Repurposing drugs to target the diabetes epidemic
    240. A systematic Review on Antidiabetic medicinal Plants
    241. Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight …
    242. The new direction in medical management of chronic heart failure with reduced ejection fraction
    243. Role of nutrient transporters in lifestyle-related diseases
    244. SGLT-2 inhibitors-hope or hype?-an updated review
    245. Biology of human sodium Glucose transporters
    246. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes
    247. New-Onset Diabetes after Kidney Transplantation: Diagnosis, Risk Factors, and Management
    248. The role of glucagon in the acute therapeutic effects of SGLT2 Inhibition
    249. New pharmacological approaches to diabetes management
    250. Diuretic activity of methanolic extract of Physalis minima leaves
    251. New therapeutic strategies for type 2 diabetes CME
    252. Dandelion: Phytochemistry and clinical potential
    253. The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes
    254. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin
    255. Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory
    256. Glucose lowering treatment modalities of type 2 diabetes mellitus
    257. www. OpenCME. org/course/where-do-sglt2-inhibitors-fit-spectrum-of-treatment-of-t2dm
    258. A systematic review on effect of canagliflozin in special population
    259. Selected biologically active substances and healing properties of dandelion (Taraxacum officinale)
    260. Hypoglycaemic activity and nephro-protectective effect of Bauhinia rufescens in alloxan-induced diabetic rats
    261. Lipid Accumulation Product Combined With Urine Glucose Excretion Improves the Efficiency of Diabetes Screening in Chinese Adults
    262. The Role of Adipose Tissue in Diabetic Kidney Disease
    263. Antihyperglycemic Studies on the Leaf Extract and Active Fractions of Newbouldia laevis (Bignoniaceae)
    264. Challenges for the treatment of diabetes mellitus
    265. Plants having potential antidiabetic activity: a review
    266. Intraoperative Diagnosis of Sodium-Glucose Cotransporter 2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis: A Case Report
    267. Treatment approach to type 2 diabetes: Past, present and future
    268. OP8-3: Adaptive changes of transposed ileum and their potential roles in the metabolic benefits of bariatric surgery
    269. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
    270. The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions
    271. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
    272. The effect of dapagliflozin on clinical, metabolic and Renal parameters in type 2 diabetic patient in University of Malaya Medical Centre: A single centre experience/Ho …
    273. Antidiabetics Review on Natural Products
    274. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations
    275. Potential role of yoga in management of the ominous octet: Adding a new facet to type 2 diabetes management and prevention
    276. Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote Glucose disposal and inflammation
    277. Effect of saffron (Crocus sativus L.) on lipid profile, glycemic indices and antioxidant status among overweight/obese prediabetic individuals: A double-blinded …
    278. The metabolic model of heart failure: the role of sodium Glucose co-transporter-2 (SGLT-2) Inhibition
    279. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload
    280. Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
    281. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution
    282. Bioequivalence of fixed‐dose combinations of dapagliflozin and metformin with single‐component tablets in healthy subjects and the effect of food on bioavailability
    283. Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in …
    284. PE-4: Effects of polydextrose on glycemic and insulinemic responses in healthy normal weight and overweight women when consumed during a breakfast meal
    285. Assessing the kidney function parameters glomerular filtration rate and effective Renal plasma flow with dynamic FDG-PET/MRI in healthy subjects
    286. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study
    287. The therapeutic journey of benzimidazoles: a review
    288. Sodium-Glucose cotransporter 2 inhibitors and cardiovascular outcomes
    289. Glucose transport at the Renal brush border membrane: GLUT2 and the involvement of PKC-βI
    290. Can we trust the positivity of semi-quantitative Glucose measurement in the urine?
    291. Can we trust the positivity of semi-quantitative Glucose measurement in the urine?
    292. Our Practice
    293. Asian Journal of Phytomedicine and Clinical Research
    294. Identification of key nodes of type 2 diabetes mellitus protein interactome and study of their interactions with phloridzin
    295. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review …
    296. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
    297. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study
    298. Novel therapeutic agents for the treatment of diabetic kidney disease
    299. Pharmacognosy, phytochemistry, pharmacology and clinical applications of Taraxacum officinale
    300. The Future of Diabetes Therapy
    301. Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin: Original article: Roden M, Weng J …
    302. Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 Inhibitors in Type 2 DM Subjects
    303. Anti-ulcerogenic effects and anti-oxidative properties of Ceiba pentandra leaves on alloxan-induced diabetic rats
    304. A new analytical method for determination of dolutegravir and rilpivirine in pharmaceutical formulations by RP-HPLC method
    305. Arterial pressure lability is improved by sodium-Glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats
    306. Pancreatic islet regeneration and some liver biochemical parameters of leaf extracts of Vitex doniana in normal and streptozotocin–induced diabetic albino …
    307. Our Practice Newsletter: By Pharmacists For Pharmacists, issue 3
    308. Diabetes mellitus and use of medicinal plants for its treatment
    309. Present and future challenges in Type 2 diabetes
    310. Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes
    311. Antidiabetic attributes of desert and steppic plants: a review
    312. Diabetes mellitus and hypertension: a dual threat
    313. Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL/6J mice
    314. Therapeutic role of fibroblast growth factor 21 (FGF21) in the amelioration of chronic diseases
    315. Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET …
    316. Drug utilization patterns in patients with diabetes initiating sodium Glucose co-transporter-2 inhibitors (SGLT2i) in Japan: a multi-database study (2014–2017)
    317. Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study
    318. Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-Glucose cotransporter SGLT1 with high affinity
    319. Hormone‐substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active‐controlled DURATION‐8 study
    320. Some selected medicinal plants with antidiabetic potentials
    321. Pharmacologic treatment options for type 1 diabetes: what’s new?
    322. Contribution to the study of medicinal plants used in the treatment of diabetes, obesity and hypertension in Tafilalet region (Morocco)
    323. The physiological effects of dandelion (Taraxacum officinale) in type 2 diabetes
    324. Diabetes and cardiovascular risk in Renal transplant patients
    325. Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
    326. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials
    327. OP8-2: The effect of bariatric surgery on fatty acid uptake and associated gene expression in abdominal subcutaneous adipose tissue of morbidly obese women
    328. Repurposing existing drugs for COVID-19: an endocrinology perspective
    329. SGLT-2 Inhibition in the kidney: changing paradigms in the treatment of type 2 diabetes mellitus
    330. Pharmacological profile of tofogliflozin, a novel SGLT2 inhibitor, in preclinical studies
    331. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose …
    332. Approach to diabetes management in patients with CVD
    333. Implications of the CANVAS Study in Reducing Cardiovascular Outcomes
    334. Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction
    335. The Ameliorative Potential of Saffron Against the Histological and Immunohistochemical Changes in Kidney of Albino Mice Due to Streptozotocin-Induced Diabetes …
    336. Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
    337. PE-1: Comparing the efficacy of different health education tools for improving blood Glucose control in patients with type 2 diabetes
    338. PE-2: Assessment of universal healthcare coverage of diabetes prevalence in a north India district: a rapid survey in urban and rural areas
    339. Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/Glucose‐cotransporter 2 …
    340. Hypoglycaemic and Hypolipidemic Effects of Black Brand of Lipton Tea (Camellia sinensis) on Normal Male Albino Rats
    341. Anti sense and sensibility: Renal and skin effects of (antisense) oligonucleotides
    342. β-Cell plasticity
    343. Hypoglycemic Activity of Extract Leaf and Root Plant of Jombang (Taraxacum Officinale) in Alloxan-Induced Diabetic Wistar Male Rats
    344. Benzimidazole: Journey from Single Targeting to Multitargeting Molecule
    345. Gut mechanisms linking intestinal sweet sensing to glycemic control
    346. Hypoglycemic Activity of Extract Leaf and Root Plant of Jombang (Taraxacum Officinale) in Alloxan-Induced Diabetic Wistar Male Rats
    347. Evaluation of antioxidant, hypoglycemic and hypolipidemic effects of the phytoconstituents of Cinnamomum tamala in rats
    348. OP8-4: Plasmalogens regulate macrophage polarization and protect against adipose tissue inflammation in high fat diet-fed mice
    349. PE-3: Artificial sweeteners content in sugar free products and public attitude of use in Muscat, Oman
    350. Silica-coated magnetic nanoparticles induce Glucose metabolic dysfunction in vitro via the generation of reactive oxygen species
    351. The relationship between peripheral Glucose utilisation and insulin sensitivity in the regulation of hepatic Glucose production: studies in normal and alloxan‐diabetic …
    352. Role of Retama Raetam on Gentamicin-Induced Acute Kidney Injury in Experimental Rat Model
    353. Nonlinear ODE mathematical analysis of the insulin-Glucose model in the presence of a condition in glycemia function H (G).
    354. A review: Medicinal plants and its impact on diabetes
    355. Antidiabetic, antioxidant and anti inflammatory properties of water and n-butanol soluble extracts from Saharian Anvillea radiata in high-fat-diet fed mice
    356. Focused Ultrasound Modulation of Hepatic Neural Plexus Restores Glucose Homeostasis in Diabetes
    357. Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy
    358. Hypoglycemic and hypolipidemic effects of ethyl acetate leaf extract of Vitex simplicifolia in alloxan induced diabetic wister rats
    359. Role of Retama Raetam on Gentamicin-Induced Acute Kidney Injury in Experimental Rat Model Medhat M. Menshawy1 Abdel Razik H. Farrag 2, Sayed A. El …
    360. Role of Canagliflozin on function of CD34+ ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
    361. The Effect of Empagliflozin on Left Ventricular Mass and Myocardial Extracellular Volume in Patients with Type 2 Diabetes and Cardiovascular Disease
    362. Cress seed (lepidium sativum) role in the healthy processed spread cheese and its anti-diabetic activity
    363. Possible ways to improve postprandial Glucose control in type 1 diabetes
    364. New therapeutic agents for glycemic control in diabetes mellitus
    365. Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014–2017)
    366. Role of some Egyptian medicinal plants against liver and kidney toxicity induced by cadmium chloride
    367. A new analytical method for determination of ledipasvir and sofosbuvir in pharmaceutical formulations by HPLC method
    368. Evaluation of medicinal plants used to diabetes treatment
    369. Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a …
    370. Skeletal muscle basal AMP-activated protein kinase activity is chronically elevated in alloxan-diabetic dogs: impact of exercise
    371. HERBAL INTERVENTIONS IN MANAGING DIABETES MELLITUS: A REVIEW
    372. Options for empagliflozin in combination therapy in type 2 diabetes mellitus
    373. Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial
    374. LEELA MADHURI POLA1
    375. The effects of plant-derived oleanolic acid on kidney function in male Sprague-Dawley rats and, in cell lines of the kidney and liver.
    376. Novel research strategies of benzimidazole derivatives: a review
    377. Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
    378. Type 2 diabetes mellitus and the elderly: an update on drugs used to treat glycaemia
    379. Combined effect of canagliflozin and exercise training on high-fat diet-fed mice
    380. Natural Products Derived from the Mediterranean Diet with Antidiabetic Activity: from Insulin Mimetic Hypoglycemic to Nutriepigenetic Modulator Compounds
    381. Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus
    382. Prevailing hyperglycemia is critical in the regulation of Glucose metabolism during exercise in poorly controlled alloxan-diabetic dogs
    383. Factors influencing seed germination of the pastoral plant Retama raetam subsp. bovei (Fabaceae): interactive effects of fruit morphology, salinity, and osmotic stress
    384. on Pharmacometrics 2014 (ACoP5)
    385. Polyphenols of apples and their potential health benefits
    386. Endothelial Dysfunction in Diabetes: An Update on Mechanisms and Therapeutic Targets
    387. Studies on kidney pathophysiological analyses in SDT fatty rat, a novel obese diabetic model
    388. 19 Interview| Prof. dr. U. Beuers
    389. Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study.
    390. Evaluation of the stability of exenatide in aqueous solutions
    391. Clinical Trial Number NCT02635386
    392. Medicinal plants used for the treatment of diabetes and its long-term complications
    393. Should the recommendation of the American Association of Clinical Endocrinologists for a hemoglobin A1c target of 6.5% be modified? A critical reappraisal of recent …
    394. Fruit and vegetable waste management: Conventional and emerging approaches
    395. Diabetes mellitus and cardiovascular disease in the elderly
    396. CONTINUOUS Glucose MONITORING 1-OR
    397. NURDIANA BINTI SAMSULRIZAL
    398. The in vitro and in vivo anti-oxidative and anti-diabetic effects of some African medicinal plants and the identification of the bioactive compounds.
    399. In-depth Studies of the Antioxidant Profile of Aegle marmelos and Its Impact on Healthy and Type II Diabetes Mellitus Subjects
    400. Mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Effective diet against o minous octet
    401. Investigation of CPR knowledge dependence on driving experience and participation in first aid training
    402. The development and health of premature infants born before the 30th pregnancy week at the age of six
    403. Evaluation of mechanical power caused by different mechanical lung ventilation methods
    404. Neurological complications of pandemic A (H1N1) 2009PDM, post-pandemic (H1N1) V, and seasonal influenza A
    405. INSULIN TREATMENT IN TYPE 2 DIABETES
    406. General anesthesia from patients perspective: what myths are most common?
    407. Roots/Health Benefits of Apples

     

    Share
    0
    INTERSTELLAR BLEND

    Related posts

    June 1, 2022

    STEM CELL THERAPY


    Read more
    June 1, 2022

    PHYTOCHEMICALS


    Read more
    June 1, 2022

    SMALLPOX


    Read more

    Comments are closed.

    Recent Posts

    • STEM CELL THERAPY
    • PHYTOCHEMICALS
    • SMALLPOX
    • ELLAGIC ACID
    • CYANIDIN
    © 2022 Interstellar Blends | Activate Your Super Powers!. © 2019 Interstellar Blends | Activate Your Super Powers!. All Rights Reserved.

    Mandatory FDA Disclaimer
    Privacy Policy
    Terms and Conditions
    Have Questions?
    Contact Gavin Robert McGowen Here

    Join the following facebook groups to learn more:
    Ultimate Weightloss Challenge , Dry Fasting, Longevity Agents , Interstellar Blend Seven Sages, The Infinitely Postive, THE INTERSTELLAR BLEND CHALLENGE: Fluid Restricted Fasting w/ Superherbs

    Love this Website? Contact David Rodriguez to build you one!